Abstract
Biotech products and processes are complex. Our understanding of how the process affects product quality is incomplete and that of how the various quality attributes of the product affect the clinical safety and efficacy is even more limited. Quality by Design (QbD)-based process and product development aims at improving this understanding. In this chapter, we briefly introduce the concept of QbD in the context of biotherapeutics. Next we discuss the various unit operations that together make a typical process. Recent advancements in the manufacturing of biotech therapeutics will also be presented. The importance of identifying the underlying relationship between the quality attributes of the product and clinical safety and efficacy for ultimate realization of QbD goals is discussed in the last section of the chapter. Future perspective of the increasingly important role that QbD is likely to play for the manufacturing of drugs for an increasingly global market is presented as the concluding note of this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weinacker D et al (2013) Applications of recombinant Pichia pastoris in the healthcare industry. Braz J Microbiol 44(4):1043–1048
Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32(10):992–1000
Rathore AS (2009) Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 27(9):546–553
Rathore AS, Winkle H (2009) Quality by design for biopharmaceuticals. Nat Biotechnol 27(1):26–34
Tsuruta LR, Lopes dos Santos M, Moro AM (2015) Biosimilars advancements: moving on to the future. Biotechnol Prog 31(5):1139–1149
Schellekens H (2004) How similar do ‘biosimilars’ need to be? Nat Biotechnol 22(11):1357–1359
CHMP (2005) Guideline on similar biological medicinal products, European Medicines Agency, 437, London
Rathore AS (2009) Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol 27(12):698–705
Cai X, Wake A, Gouty D (2013) Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. Bioanalysis 5(5):517–520
Beck A et al (2013) Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC Trends Anal Chem 48:81–95
Chelius D et al (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2(3):309–319
Rosati S et al (2013) Tackling the increasing complexity of therapeutic monoclonal antibodies with mass spectrometry. TrAC Trends Anal Chem 48:72–80
Singleton CA (2014) MS in the analysis of biosimilars. Bioanalysis 6(12):1627–1637
Xie H et al (2010) Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2(4):379–394
Rathore AS, Mhatre R (2008) In: Rathore AS, Mhatre R (eds) Quality by design for biopharmaceuticals: principles and case studies. Wiley, Hoboken
Rathore AS et al (2015) Continuous processing for production of biopharmaceuticals. Prep Biochem Biotechnol 45(8):836–849
Rathore AS et al (2015) Process analytical technologies in biopharmaceutical process development. J Chem Technol Biotechnol 90(2):213–214
Hemmerich J et al (2014) Comprehensive clone screening and evaluation of fed-batch strategies in a microbioreactor and lab scale stirred tank bioreactor system: application on Pichia pastoris producing Rhizopus oryzae lipase. Microb Cell Fact 13(1):36
Kumar V, Rathore AS (2014) Two-stage chromatographic separation of aggregates for monoclonal antibody therapeutics. J Chromatogr A 1368:155–162
Legmann R et al (2009) A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol Bioeng 104(6):1107–1120
Persad A et al (2013) Comparative performance of decoupled input–output linearizing controller and linear interpolation PID controller: enhancing biomass and ethanol production in Saccharomyces cerevisiae. Appl Biochem Biotechnol 169(4):1219–1240
Rathore AS et al (2009) Case study and application of process analytical technology (PAT) towards bioprocessing: use of tryptophan fluorescence as at-line tool for making pooling decisions for process chromatography. Biotechnol Prog 25(5):1433–1439
Roychoudhury P et al (2007) Multiplexing fibre optic near infrared (NIR) spectroscopy as an emerging technology to monitor industrial bioprocesses. Anal Chim Acta 590(1):110–117
ICH Guidelines Q 11, 20AD. Pharmaceutical development Q8. ICH Harmonised Tripartite Guideline, 8(August), pp 1–28
Rathore AS (2014) QbD/PAT for bioprocessing: moving from theory to implementation. Curr Opin Chem Eng 6:1–8
ICH Guideline (2012) Development and manufacture of drug substances (chemical entities and biotechnological/biological entities) Q11, European medicines agency, May 2011
ICH Guideline (2008) Pharmaceutical quality system Q10, current step, 4
Rathore AS, Bhambure R, Ghare V (2010) Process analytical technology (PAT) for biopharmaceutical products. Anal Bioanal Chem 398(1):137–154
Read EK, Park JT et al (2010) Process analytical technology (PAT) for biopharmaceutical products: part I. Concepts and applications. Biotechnol Bioeng 105(2):276–284
Read EK, Shah RB et al (2010) Process analytical technology (PAT) for biopharmaceutical products: part II. Concepts and applications. Biotechnol Bioeng 105(2):285–295
Gronemeyer P, Ditz R, Strube J (2014) Trends in upstream and downstream process development for antibody manufacturing. Bioengineering 1(4):188–212
Haigney S (2013) QbD and PAT in upstream and downstream processing. BioPharm Int 26(7):28–37
ICH Expert Working Group (2005) Quality risk management Q9. ICH Harmonised Tripartite Guideline (November), pp 1–23
Gomes J, Chopda VR, Rathore AS (2015) Integrating systems analysis and control for implementing process analytical technology in bioprocess development. J Chem Technol Biotechnol 90(4):583–589
Raju TS (2003) Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. Bioprocess Int 1:44–53
Biechele P et al (2015) Sensor systems for bioprocess monitoring. Eng Life Sci 15(5):469–488
Jain E, Kumar A (2008) Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv 26(1):46–72
Rouiller Y et al (2012) Application of quality by design to the characterization of the cell culture process of an Fc-fusion protein. Eur J Pharm Biopharm 81(2):426–437
Goldfeld M et al (2014) Advanced near-infrared monitor for stable real-time measurement and control of Pichia pastoris bioprocesses. Biotechnol Prog 30(3):749–759
Sandor M et al (2013) NIR-spectroscopy for bioprocess monitoring & control. BMC Proc 7(Suppl 6):P29
Roychoudhury P, Harvey LM, McNeil B (2006) The potential of mid infrared spectroscopy (MIRS) for real time bioprocess monitoring. Anal Chim Acta 571(2):159–166
Schmidt-Hager J et al (2014) Noninvasive online biomass detector system for cultivation in shake flasks. Eng Life Sci 14(5):467–476
Zhao L et al (2015) Advances in process monitoring tools for cell culture bioprocesses. Eng Life Sci 15(5):459–468
Craven S, Whelan J (2015) Process analytical technology and quality-by-design for animal cell culture. In: Al-Rubeai M (ed) Animal cell culture, Cell engineering. Springer, Switzerland, pp 647–688
Schwamb S, Puskeiler R, Wiedemann P (2015) Monitoring of cell culture. In: Al-Rubeai M (ed) Animal cell culture, Cell engineering. Springer, Switzerland, pp 185–221
Kuystermans D, Mohd A, Al-Rubeai M (2012) Automated flow cytometry for monitoring CHO cell cultures. Methods 56(3):358–365
Bradley SA et al (2010) Fermentanomics: monitoring mammalian cell cultures with NMR spectroscopy. J Am Chem Soc 132(28):9531–9533
Read EK et al (2013) Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture. Biotechnol Prog 29(3):745–753
Clavaud M et al (2013) Chemometrics and in-line near infrared spectroscopic monitoring of a biopharmaceutical Chinese hamster ovary cell culture: prediction of multiple cultivation variables. Talanta 111:28–38
Lourenço ND et al (2012) Bioreactor monitoring with spectroscopy and chemometrics: a review. Anal Bioanal Chem 404(4):1211–1237
Bhushan N, Hadpe S, Rathore AS (2012) Chemometrics applications in biotech processes: assessing process comparability. Biotechnol Prog 28(1):121–128
Mercier SM et al (2014) Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations. Trends Biotechnol 32(6):329–336
Rathore AS et al (2014) Chemometrics application in biotech processes: assessing comparability across processes and scales. J Chem Technol Biotechnol 89(9):1311–1316
Rathore AS, Mittal S, Pathak M, Arora A (2014) Guidance for performing multivariate data analysis of bioprocessing data: pitfalls and recommendations. Biotechnol Prog 30(4):967–973
Rathore AS, Kumar V et al (2014) Mechanistic modeling of viral filtration. J Membr Sci 458:96–103
Rathore AS, Bhushan N, Hadpe S (2011) Chemometrics applications in biotech processes: a review. Biotechnol Prog 27(2):307–315
Vaidyanathan S et al (2001) Assessment of near-infrared spectral information for rapid monitoring of bioprocess quality. Biotechnol Bioeng 74(5):376–388
Kirdar AO, Green KD, Rathore AS (2008) Application of multivariate data analysis for identification and successful resolution of a root cause for a bioprocessing application. Biotechnol Prog 24(3):720–726
Kirdar AO et al (2010) Application of near-infrared (NIR) spectroscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Prog 26(2):527–531
Rathore AS et al (2012) Chemometrics applications in biotechnology processes: predicting column integrity and impurity clearance during reuse of chromatography resin. Biotechnol Prog 28(5):1308–1314
Pearson S (2015) Smart process development strategies. Genet Eng Biotechnol News, pp 1–2
Bhambure R, Kumar K, Rathore AS (2011) High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol 29(3):127–135
Lattermann C, Büchs J (2014) Microscale and miniscale fermentation and screening. Curr Opin Biotechnol 35C:1–6
Pollard D (2014) Are automated disposable small-scale reactors set to dominate the future of pharmaceutical bioprocess development? Pharm Bioprocess 2(1):9–12
Rameez S et al (2014) High-throughput miniaturized bioreactors for cell culture process development: reproducibility, scalability, and control. Biotechnol Prog 30(3):718–727
Razinkov V et al (2015) Automation and high-throughput technologies in biopharmaceutical drug product development with QbD approaches. In: Jameel F et al (eds) Quality by design for biopharmaceutical drug product development SE - 20, AAPS advances in the pharmaceutical sciences series. Springer, New York, pp 475–510
Simon LL et al (2015) Assessment of recent process analytical technology (PAT) trends: a multiauthor review. Org Process Res Dev 19(1):3–62
Clark EDB (2001) Protein refolding for industrial processes. Curr Opin Biotechnol 12(2):202–207
Bade PD, Kotu SP, Rathore AS (2012) Optimization of a refolding step for a therapeutic fusion protein in the quality by design (QbD) paradigm. J Sep Sci 35(22):3160–3169
Rathore AS et al (2013) Refolding of biotech therapeutic proteins expressed in bacteria: review. J Chem Technol Biotechnol 88(10):1794–1806
Calvo B, Zuñiga L (2012) The US approach to biosimilars. BioDrugs 26(6):357–361
O’Connor A, Rogge M (2013) Nonclinical development of a biosimilar: the current landscape. Bioanalysis 5(5):537–544
Tsiftsoglou A et al (2014) Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe. BioDrugs 28(6):479–486
Rathore AS, Singh SK (2014) Clinical and non-clinical aspects of biosimilar development. BioQuality 9:1–6
Kumar V, Bhalla A, Rathore AS (2014) Design of experiments applications in bioprocessing: concepts and approach. Biotechnol Prog 30(1):86–99
Saremirad P et al (2014) Multi-variable operational characteristic studies of on-column oxidative protein refolding at high loading concentrations. J Chromatogr A 1359:70–75
Przybycien TM, Pujar NS, Steele LM (2004) Alternative bioseparation operations: life beyond packed-bed chromatography. Curr Opin Biotechnol 15(5):469–478
Williams A, Frasca V (2001) Ion-exchange chromatography. In: Current protocols in protein science, vol 15(8.2), pp 8.2.1–8.2.30
Barth HG, Jackson C, Boyes BE (1994) Size exclusion chromatography. Anal Chem 66(12):595R–620R
Roque ACA, Silva CSO, Taipa MA (2007) Affinity-based methodologies and ligands for antibody purification: advances and perspectives. J Chromatogr A 1160(1–2):44–55
Ochoa J-L (1978) Hydrophobic (interaction) chromatography. Biochimie 60(1):1–15
Bhambure R, Rathore AS (2013) Chromatography process development in the quality by design paradigm I: establishing a high-throughput process development platform as a tool for estimating ‘characterization space’ for an ion exchange chromatography step. Biotechnol Prog 29(2):403–414
Rathore AS, Kapoor G (2015) Application of process analytical technology for downstream purification of biotherapeutics. J Chem Technol Biotechnol 90(2):228–236
Chhatre S et al (2009) Use of PAT principles for the open-loop control of laboratory and pilot-scale chromatography columns. J Chem Technol Biotechnol 84(9):1314–1322
Kamga M-H et al (2013) Quantification of protein mixture in chromatographic separation using multi-wavelength UV spectra. Biotechnol Prog 29(3):664–671
Vyas V, Nellis D, Burnette A (2009) BIOT-396. In: Abstracts of papers, 238th ACS national meeting, Washington DC
Mendhe R et al (2015) Comparison of PAT based approaches for making real-time pooling decisions for process chromatography – use of feed forward control. J Chem Technol Biotechnol 90(2):341–348
Kaltenbrunner O et al (2012) Risk-benefit evaluation of on-line high-performance liquid chromatography analysis for pooling decisions in large-scale chromatography. J Chromatogr A 1241:37–45
Rathore AS et al (2008) Case study and application of process analytical technology (PAT) towards bioprocessing: II. Use of ultra-performance liquid chromatography (UPLC) for making real-time pooling decisions for process chromatography. Biotechnol Bioeng 101(6):1366–1374
Rathore AS, Shirke A (2011) Recent developments in membrane-based separations in biotechnology processes: review. Prep Biochem Biotechnol 41(4):398–421
Rathore AS, Sharma A, Chilin D (2006) Applying process analytical technology to biotech unit operations. BioPharm Int 19(8):48–57
Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28(5):253–261
Croughan MS, Konstantinov KB, Cooney C (2015) The future of industrial bioprocessing: batch or continuous? Biotechnol Bioeng 112(4):648–651
Warikoo V et al (2012) Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 109(12):3018–3029
Van Reis R, Zydney A (2001) Membrane separations in biotechnology. Curr Opin Biotechnol 12(2):208–211
Łącki KM (2014) High throughput process development in biomanufacturing. Curr Opin Chem Eng 6:25–32
Muthukumar S, Rathore AS (2013) High throughput process development (HTPD) platform for membrane chromatography. J Membr Sci 442:245–253
Orr V et al (2013) Recent advances in bioprocessing application of membrane chromatography. Biotechnol Adv 31(4):450–465
Fröhlich H et al (2012) Membrane technology in bioprocess science. Chem Ing Tech 84(6):905–917
Fraud N, Kuczewski M, Hirai M (2009) Hydrophobic membrane adsorbers for large-scale downstream processing. BioPharm Int 2009(suppl 22):24–27
Limonta M et al (2010) The purification of plasmid DNA for clinical trials using membrane chromatography. BioPharm Int 23(2):46–54
Riordan W et al (2009) Design of salt‐tolerant membrane adsorbers for viral clearance. Biotechnol Bioeng 103(5):920–929
Yu D, Ghosh R (2010) Purification of PEGylated protein using membrane chromatography. J Pharm Sci 99(8):3326–3333
Anuraj N et al (2012) An all-aqueous route to polymer brush-modified membranes with remarkable permeabilites and protein capture rates. J Membr Sci 389:117–125
Kuczewski M et al (2010) Development of a polishing step using a hydrophobic interaction membrane adsorber with a PER. C6®‐derived recombinant antibody. Biotechnol Bioeng 105(2):296–305
Bensch M, Schulze Wierling P, von Lieres E, Hubbuch J (2005) High throughput screening of chromatographic phases for rapid process development. Chem Eng Technol 28(11):1274–1284
Coffman JL, Kramarczyk JF, Kelley BD (2008) High-throughput screening of chromatographic separations: I. Method development and column modeling. Biotechnol Bioeng 100(4):605–618
Kelley BD, Switzer M, Bastek P, Kramarczyk JF, Molnar K, Yu T, Coffman J (2008) High-throughput screening of chromatographic separations: IV. Ion‐exchange. Biotechnol Bioeng 100(5):950–963
Kramarczyk JF, Kelley BD, Coffman JL (2008) High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol Bioeng 100(4):707–720
Strauss DM et al (2010) Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production. Biotechnol Prog 26(3):750–755
Wiendahl M et al (2009) A novel method to evaluate protein solubility using a high throughput screening approach. Chem Eng Sci 64(17):3778–3788
Kong S, Aucamp J, Titchener-Hooker NJ (2010) Studies on membrane sterile filtration of plasmid DNA using an automated multiwell technique. J Membr Sci 353(1):144–150
Ahmad SS, Dalby PA (2011) Thermodynamic parameters for salt‐induced reversible protein precipitation from automated microscale experiments. Biotechnol Bioeng 108(2):322–332
Grant Y, Matejtschuk P, Dalby PA (2009) Rapid optimization of protein freeze‐drying formulations using ultra scale‐down and factorial design of experiment in microplates. Biotechnol Bioeng 104(5):957–964
Cramer SM, Holstein MA (2011) Downstream bioprocessing: recent advances and future promise. Curr Opin Chem Eng 1(1):27–37
Voitl A, Müller-Späth T, Morbidelli M (2010) Application of mixed mode resins for the purification of antibodies. J Chromatogr A 1217(37):5753–5760
Naik AD et al (2011) Performance of hexamer peptide ligands for affinity purification of immunoglobulin G from commercial cell culture media. J Chromatogr A 1218(13):1691–1700
Rao G, Moreira A, Brorson K (2009) Disposable bioprocessing: the future has arrived. Biotechnol Bioeng 102(2):348–356
Chennamsetty N et al (2010) Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 114(19):6614–6624
Jordan JL et al (2009) Structural understanding of stabilization patterns in engineered bispecific Ig‐like antibody molecules. Proteins 77(4):832–841
Perchiacca JM, Bhattacharya M, Tessier PM (2011) Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 79(9):2637–2647
Berkowitz SA et al (2012) Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 11(7):527–540
Eon-Duval A, Broly H, Gleixner R (2012) Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog 28(3):608–622
Joubert MK et al (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266–25279
Hou Y et al (2011) Improved process analytical technology for protein a chromatography using predictive principal component analysis tools. Biotechnol Bioeng 108(1):59–68
Tescione L et al (2015) Application of bioreactor design principles and multivariate analysis for development of cell culture scale down models. Biotechnol Bioeng 112(1):84–97
Kirdar AO et al (2007) Application of multivariate analysis toward biotech processes: case study of a cell‐culture unit operation. Biotechnol Prog 23(1):61–67
Barbosa MDFS et al (2012) Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics. Drug Discov Today 17(23):1282–1288
Kenett RS, Kenett DA (2008) Quality by design applications in biosimilar pharmaceutical products. Accred Qual Assur 13(12):681–690
Sampath K (2013) Drug product development of biosimilars: QbD based approach and strategies. In: Abstracts of papers of the American Chemical Society. American Chemical Society, Washington, DC
Zalai D, Dietzsch C, Herwig C (2013) Risk-based process development of biosimilars as part of the quality by design paradigm. PDA J Pharm Sci Technol 67:569–580
Velayudhan A (2014) Overview of integrated models for bioprocess engineering. Curr Opin Chem Eng 6:83–89
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Rathore, A.S., Singh, S.K. (2016). Production of Protein Therapeutics in the Quality by Design (QbD) Paradigm. In: Sauna, Z., Kimchi-Sarfaty, C. (eds) Protein Therapeutics. Topics in Medicinal Chemistry, vol 21. Springer, Cham. https://doi.org/10.1007/7355_2015_5004
Download citation
DOI: https://doi.org/10.1007/7355_2015_5004
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41816-2
Online ISBN: 978-3-319-41818-6
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)